Buscar
Jazz Pharmaceuticals PLC
JAZZAñadir a la lista de seguimiento
252.860USD
-5.520-2.14%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
15.53BCap. mercado
613.23P/E TTM
Más Datos de Jazz Pharmaceuticals PLC Compañía
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Información de Jazz Pharmaceuticals PLC
Símbolo de cotizaciónJAZZ
Nombre de la empresaJazz Pharmaceuticals PLC
Fecha de salida a bolsaJan 18, 2012
Director ejecutivoGala (Renee D)
Número de empleados2800
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 18
DirecciónFifth Floor, Waterloo Exchange
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal- -
Teléfono35316347800
Sitio Webhttps://www.jazzpharma.com/
Símbolo de cotizaciónJAZZ
Fecha de salida a bolsaJan 18, 2012
Director ejecutivoGala (Renee D)
Ejecutivos de Jazz Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Jazz Pharmaceuticals PLC?
Los cinco principales accionistas de Jazz Pharmaceuticals PLC son: Mr. Seamus C. Mulligan
¿Cuántas instituciones poseen acciones de Jazz Pharmaceuticals PLC (JAZZ)?
A fecha de 2026Q1, 1229 instituciones poseen acciones de Jazz Pharmaceuticals PLC, con un valor de mercado combinado de aproximadamente 70.31M, lo que representa el 112.06% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -754072.00.
¿Cuál es la mayor fuente de ganancias de Jazz Pharmaceuticals PLC?
El 2026Q1, el segmento empresarial Xywav generó la ganancia más alta para Jazz Pharmaceuticals PLC, ascendiendo a 1.66B y representando el 38.83% de la ganancia total.